Free Trial
NASDAQ:MNOV

MediciNova 2/15/2024 Earnings Report

MediciNova logo
$1.32 +0.03 (+2.33%)
As of 02:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

MediciNova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MediciNova Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

MediciNova's next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

MediciNova Earnings Headlines

Q2 Earnings Estimate for MediciNova Issued By B. Riley
What is B. Riley's Estimate for MediciNova FY2025 Earnings?
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
B. Riley Upgrades MediciNova (NASDAQ:MNOV) to "Strong-Buy"
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV), a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

View MediciNova Profile

More Earnings Resources from MarketBeat